TherimuneX Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

TherimuneX General Information


Developer of inflammasome signaling platform designed to exploit the commercial applications of a new medical discovery. The company's platform relates to a new family of endogenous lipopeptides and their immune regulating properties leading to the development of a new therapeutic peptide, enabling doctors to treat and prevent infectious diseases including cancer and scleroderma.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 5110 Campus Drive
  • Plymouth Meeting, PA 19462
  • United States
+1 (610) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TherimuneX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Jun-2018 Completed Out of Business
3. Debt - General Completed Generating Revenue
2. Later Stage VC 01-Nov-2011 Completed Generating Revenue
1. Grant 01-Jan-2009 $636K Completed Startup
To view TherimuneX’s complete valuation and funding history, request access »

TherimuneX Patents

TherimuneX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20120238491-A1 Immunologically active lipopeptides and methods for use thereof Inactive 10-Apr-2009 000000000
AU-2009240516-B2 Peptidyl diacylglycerides Inactive 24-Apr-2008 000000000
AU-2009240516-A1 Peptidyl diacylglycerides Active 24-Apr-2008 000000000
CA-2727973-A1 Peptidyl diacylglycerides Active 24-Apr-2008 000000000
CA-2727973-C Peptidyl diacylglycerides Active 24-Apr-2008 A61K38/10
To view TherimuneX’s complete patent history, request access »